Quantel Medical receives FDA approval for the new A/B/S/UBM ultrasound platform ABSolu®

Quantel Medical receives FDA approval for the new A/B/S/UBM ultrasound platform ABSolu®

Quantel Medical receives FDA approval for the new A/B/S/UBM ultrasound platform ABSolu®

Quantel Medical today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on March 25, 2019 for the New A/B/S Ultrasound Platform: ABSolu®.

ABSolu® is our new ultrasound platform replacing our flagship ultrasound system Aviso. It is the achievement of years of work carried out by our R&D Department in collaboration with ultrasound specialists and we can say that once again, we are setting new standards in ophthalmic ultrasound imaging. For ophthalmologists looking for excellence in ultrasound imaging, ABSolu® is the ideal partner in their everyday practice.

Technological breakthroughs in the ABSolu® include:
A new 5 ring annular technology 20MHz B probe that increases the depth of field by 70% thus offering in a single scan high definition information of the vitreous, retinal wall and orbit.

ABSolu® also features standardized A Mode that complies with all the hardware and software requirements necessary for proper tissue characterization essential for tumor diagnosis as per the requirements of Prof. K. Ossoinig.

Motion sensors have been integrated in all B Mode and UBM probes allowing for an automatic and constant detection of the probe position and ultrasound beam direction (patented technology).

A new signal processing for the linear 50 MHz UBM to offer high image quality of the anterior chamber and lens.

A new full HD screen compliant with section 14 of the DICOM standard, a world premiere in ophthalmic ultrasound.

At the upcoming ASCRS Congress, to be held in San Diego May 03-07, the attendees will have the possibility to get a full review of the new ABSolu® Ultrasound Platform with its 5 ring annular technology 20MHz B probe and get additional information in exhibit booth #631.

For more information about ABSolu®, visit our website for healthcare professionnals:

The information collected through this form is recorded and transmitted to the relevant LUMIBIRD MEDICAL departments and enables us to send you any reply to a request via the contact form. The legal basis for the processing is consent. The data collected are kept for 3 years in digital format and are only transmitted to LUMIBIRD MEDICAL’s internal departments as well as to our distributors and subsidiaries. You have a right to access, rectify, contest, limit the processing of and erase data. For more information on the use of your data and your rights resulting from the amended French Data Protection Act and the GDPR, please consult our data protection policy or contact our Data Protection Officer at rgpd@lumibirdmedical.com.
For more informations on how Quantel Medical uses your data, please see our Terms and conditions.